Digestive disease week 2022 adds to the growing wave of clinical evidence supporting significant opportunity for apollo endosurgery products

Austin, tx / accesswire / may 31, 2022 / apollo endosurgery, inc. ("apollo") (nasdaq:apen), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced highlights today from data presented at digestive disease week may 21-24. "with more than 120 lectures, presentations, and posters featuring apollo products, ddw 2022 exemplified apollo's commitment to building a robust body of clinical evidence supporting the safe and effective use of overstitch ® , x-tack ® , and orbera ® ," said chas mckhann, president and ceo of apollo.
APEN Ratings Summary
APEN Quant Ranking